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In patients with nonalcoholic steatohepatitis (NASH),  the prevalence of cirrhosis is higher among 
women than men,  and hepatocellular carcinoma (HCC) develops mainly in the cirrhotic stage among 
women.  However,  the long-term outcomes in female patients with NASH have not been fully eluci-
dated,  and age,  gender and BMI were not simultaneously adjusted in previous studies on the prognosis 
of NASH.  To elucidate the outcomes in female patients with NASH,  we prospectively compared 
NASH patients with advanced ﬁbrosis (advanced NASH) with hepatitis C virus-related advanced ﬁbro-
sis (advanced CHC) patients and NASH patients with mild ﬁbrosis (mild NASH) using study cohorts 
that were adjusted for body mass index (BMI) in addition to age.  The median follow-up period was 
92.5 months.  Liver-related complication-free survival was signiﬁcantly reduced in the advanced NASH 
group compared to the mild NASH group.  No liver-related complications developed in the mild NASH 
group.  The overall survival,  liver-related complication- and cardiovascular/cerebrovascular disease-
free survival were not signiﬁcantly diﬀerent between the advanced NASH and CHC groups.  Female 
patients with NASH and advanced ﬁbrosis may have a less favorable prognosis for liver-related com-
plications than the matched cohorts with NASH and mild ﬁbrosis,  but may have a similar prognosis to 
the matched cohorts with CHC.
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on-alcoholic fatty liver disease (NAFLD),  which 
includes a wide spectrum of histopathology,  is 
the most common etiology worldwide for chronic liver 
disease [1-4].  The prevalence of NAFLD in the 
general population varies from 9ｵ to 37ｵ worldwide 
[5-12].  The prevalence of nonalcoholic steatohepati-
tis (NASH),  the more aggressive form of NAFLD,  is 
increasing with the growing epidemics of diabetes and 
obesity.  The incidence of NASH is estimated to be 
1-3ｵ among the adult Japanese population [13] and 
5.7ｵ of the general population in the Western world 
[1].  Obesity,  diabetes mellitus,  hyperlipidemia,  the 
metabolic syndrome and insulin resistance have been 
established as risk factors for primary NAFLD [1,  
14-18].  Its prevalence and related complications are 
predicted to increase [1].
　 Race or ethnicity aﬀects the prevalence of NASH 
[2].  In addition,  the clinicopathological features of 
NASH depend on age and gender,  with female patients 
becoming signiﬁcantly more prevalent with age in the 
Japanese population [13].  Age,  advanced ﬁbrosis,  
cirrhosis,  diabetes mellitus,  obesity and iron deposi-
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tion are considered to be established independent risk 
factors for hepatocellular carcinoma (HCC) in NASH 
patients [19].  Obesity in particular has been estab-
lished as a signiﬁcant risk factor for developing vari-
ous malignancies,  including liver cancers [20-25].  
Body mass index (BMI) and diabetes have been found 
to be independent risk factors associated with the 
progression of ﬁbrosis [26].  At the same time,  all-
cause mortality is higher in obese people,  primarily 
due to increased cardiovascular disease mortality and 
increased obesity-related cancer (colon,  breast,  uter-
ine,  ovarian,  renal and pancreatic) mortality [27].  
Obesity is common in Japanese patients with nonvalvu-
lar atrial ﬁbrillation,  which is closely associated with 
a history of stroke [28].  Thus,  age,  gender,  obesity 
and ﬁbrosis are closely related to the prognosis for 
NASH in the Japanese population.
　 In patients with nonalcoholic steatohepatitis (NASH),  
the prevalence in cirrhosis,  the most severe ﬁbrosis 
grade,  is higher among women than among men [29] 
and HCC develops mainly in the cirrhotic stage among 
women [30],  although HCC is reportedly less preva-
lent among women than men [22,  30,  31].  However,  
long-term outcomes in female patients with NASH have 
not been fully elucidated.  Thus,  the aim of this study 
is to elucidate the long-term outcomes in such patients.  
Several studies have compared long-term outcomes 
between NASH and chronic hepatitis C (CHC) patients 
or between NASH patients graded by ﬁbrosis severity.  
However,  most of these studies adjusted only for age 
and sex between the study cohorts.  Thus,  we adjusted 
for the important clinicopathological factors of age and 
BMI in addition to gender between the study cohorts,  
and compared the long-term outcomes of NASH with 
advanced ﬁbrosis (advanced NASH),  hepatitis C virus 
(HCV)-related advanced ﬁbrosis (advanced CHC) and 
NASH with mild ﬁbrosis (mild NASH) in a Japanese 
population.
Materials and Methods
　 Study population. Surveys of the natural his-
tory of NASH and CHC were started in 2003.  NASH 
was proved histologically.  CHC patients were positive 
for HCV viral RNA by a quantitative polymerase 
chain reaction assay.  Written informed consent was 
obtained from all NASH and CHC patients in our 
university hospital and aﬃliated hospitals,  and their 
clinicopathological data were prospectively recorded 
for the study.
　 We recruited 20 consecutive female patients with 
severe ﬁbrosis deﬁned as more severe than or equal to 
bridging ﬁbrosis (a group of advanced NASH) and 19 
consecutive female patients with mild ﬁbrosis deﬁned 
as perivenular and pericellular ﬁbrosis (a group of 
mild NASH) who presented to our hospital.  The 
female CHC patients were selected to match the age,  
BMI and degree of liver-ﬁbrosis of the advanced 
NASH patients based on the new Inuyama classiﬁca-
tion [32].  Twenty female patients with HCV-related 
advanced ﬁbrosis (a group of advanced CHC) were 
selected from among those patients without a history 
of interferon (IFN)-based therapy (such as IFN plus 
ribavirin),  who were also not receiving IFN-based 
therapy during the observation period.  Except for a 
history of IFN-based therapy,  all the patients were 
selected in a blinded fashion on the basis of age,  BMI 
and degree of liver ﬁbrosis,  without knowledge of the 
clinical outcomes.  The advanced CHC group consisted 
of 20 patients.  The details of these groups are shown 
in Tables 1 and 2.  Two independent hepatopatholo-
gists assessed the pathological ﬁndings according to 
the scoring system of Brunt et al. [33],  without 
knowledge of each patientʼs clinical and biochemical 
data.
　 Other liver disorders causing steatohepatitis or 
liver disease and HBc-Ab positive patients were 
excluded.  To reduce any lead-time bias in the survival 
analysis,  we excluded patients with a hepatic mass,  
history of CVD and cancer at the time of the liver 
biopsy.  The details on alcohol consumption were col-
lected independently by at least 2 physicians and were 
conﬁrmed by close family members.  All of the study 
participants had current and past daily alcohol intakes 
of less than not only 40g per week but also 20g per 
day and were non-smokers.
　 Diabetic type was deﬁned when fasting plasma 
glucose was 126mg/dL or higher,  and/or plasma 
glucose 2h after 75g glucose load was 200mg/dL or 
higher.  Casual plasma glucose higher than 200mg/dL 
was also regarded as indicating diabetic type.  Diabetes 
mellitus was diagnosed when the patient met the 
hyperglycemia criteria for “diabetic type” more than 
twice in separate examinations conducted on separate 
days.  The diagnosis of diabetes could be made by a 
single plasma glucose test meeting the criteria for 
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Table 1　 Comparison of the baseline characteristics of the advanced NASH and advanced CHC groups
Advanced NASH (n＝20) Advanced CHC (n＝20) P
Age＊ (years) 69,  55-81 69.5,  57-85 0.201
Body mass index＊ (kg/m2) 27.4,  22.9-35.2 27.0,  24.2-35.8 0.730
Diabetes mellitus 12 (60%)  7 (35%) 0.205
Hyperlipidemia  8 (40%)  2 (10%) 0.065
Hypertension  7 (35%) 10 (50%) 0.523
Liver ﬁbrosis (F3/F4) 2/18 0/20 0.487
Platelet count＊ (×104/uL) 10.0,  5.3-19.7 6.8,  4.9-11.4 0.010
Prothrombin time＊ (%) 73,  47-98 79.5,  60-118 0.217
AST＊ (IU/L) 49,  30-126 64,  30-101 0.787
ALT＊ (IU/L) 42,  16-188 41,  21-81 0.527
γ-GTP＊ (IU/L) 54,  14-361 29,  12-50 0.050
Albumin＊ (g/dL) 3.9,  3.3-4.7 3.5,  3.2-4.0 0.028
Total bilirubin＊ (mg/dL) 0.9,  0.4-2.0 1.1,  0.6-1.9 0.778
Total cholesterol＊ (mg/dL) 159,  113-242 137,  91-177 0.022
Triglyceride＊ (mg/dL) 91,  30-222 72,  45-129 0.449
Fasting blood sugar＊ (mg/dL) 100,  80-152 119,  84-214 0.035
HbA1c＊ (%) 5.2,  4.1-6.5 5.6,  4.5-8.5 0.394
＊Values are median,  range.  Advanced NASH,  nonalcoholic steatohepatitis with advanced ﬁbrosis; Advanced CHC,  chronic hepatitis C 
with advanced ﬁbrosis; AST,  aspartate aminotransferase; ALT,  alanine aminotransferase; γ-GTP,  gamma-glutamyltranspeptidase;  
HbA1c,  hemoglobin A1c.
Table 2　 Comparison of the baseline characteristics of the advanced NASH and mild NASH groups
Advanced NASH (n＝20) Mild NASH (n＝19) P
Age＊ (years) 69,  55-81 67,  52-78 0.260
Body mass index＊ (kg/m2) 27.4,  22.9-35.2 24.8,  20.5-31.2 0.271
Diabetes mellitus 12 (60%) 12 (63.2%) 0.899
Hyperlipidemia  8 (40%)  8 (42.1%) 0.848
Hypertension  7 (35%) 14 (73.7%) 0.025
Liver ﬁbrosis (F1/F2/F3/F4) 0/0/2/18 7/12/0/0 ＜0.001
Platelet count＊ (×104/uL) 10.0,  5.3-19.7 20.1,  13.3-24.8 ＜0.001
Prothrombin time＊ (%) 73,  47-98 82,  75-108 ＜0.001
AST＊ (IU/L) 49,  30-126 59,  29-186 0.316
ALT＊ (IU/L) 42,  16-188 61,  33-291 0.038
γ-GTP＊ (IU/L) 54,  14-361 50,  23-214 0.301
Albumin＊ (g/dL) 3.9,  3.3-4.7 4.5,  3.7-4.9 0.061
Total bilirubin＊ (mg/dL) 0.9,  0.4-2.0 0.7,  0.3-1.3 0.048
Total cholesterol＊ (mg/dL) 159,  113-242 189,  132-248 0.034
Triglyceride＊ (mg/dL) 91,  30-222 109,  50-283 0.099
Fasting blood sugar＊ (mg/dL) 100,  80-152 101,  85-174 0.119
HOMA-IR＊ 3.01,  1.56-6.50 3.15,  0.51-6.96 0.116
HbA1c＊ (%) 5.2,  4.1-6.5 6.0,  5.0-8.1 0.142
＊Values are median,  range.  Advanced NASH,  nonalcoholic steatohepatitis with advanced ﬁbrosis; Mild NASH,  nonalcoholic steatohep-
atitis with mild ﬁbrosis; AST,  aspartate aminotransferase; ALT,  alanine aminotransferase; γ-GTP,  gamma-glutamyltranspeptidase;  
HOMA-IR,  homeostasis model assessment-insulin resistance; HbA1c,  hemoglobin A1c.
“diabetic type” when one of the following 3 conditions 
existed: (1) the subject had typical symptoms of diabe-
tes mellitus (thirst,  polyuria,  polydipsia,  weight 
loss),  (2) Hemoglobin A1c was 6.5ｵ or higher,  and 
(3) unequivocal diabetic retinopathy was detected.  
Hyperlipidemia was diagnosed when the serum triglyc-
eride concentrations were above 150mg/dL and/or 
the serum cholesterol concentrations were above 
220mg/dL on at least 3 occasions or lipid-lowering 
drugs were prescribed.  Hypertension was diagnosed 
when blood pressure was greater than 140/90mmHg 
on at least 3 occasions or antihypertensive drugs were 
prescribed.
　 We prospectively compared the long-term outcomes 
of the advanced NASH group with those of the 
advanced CHC and mild NASH groups.  The study 
protocol conformed to the ethical guidelines of the 
1975 Declaration of Helsinki.
　 Data collection. Age,  height and weight were 
documented at the time of the liver biopsy.  None of 
the patients had ascites at the liver biopsy.  The type 
2 diabetes mellitus,  hypertriglycemia,  arterial hyper-
tension and CVD histories were ascertained at this 
time,  and any subsequent developments in these dis-
eases were noted during the follow-up and conﬁrmed 
by the treating physician.  The laboratory data were 
also obtained at the time of the liver biopsy.
　 Assessment of outcomes. The patients were 
monitored clinically at least every 3 months until the 
data analysis.  None of the patients were lost to fol-
low-up.  The following outcomes were evaluated: (1) 
overall survival; (2) liver-related complication-free 
survival; (3) HCC-free survival; (4) CVD complica-
tion-free survival; and (5) the causes of death,  which 
were determined from the hospital medical records 
and death certiﬁcate.  Liver-related complications 
included ascites,  hepatic encephalopathy,  variceal 
bleeding and HCC.  HCC was diagnosed if the follow-
ing conditions were met: (1) pathological features 
consistent with HCC were identiﬁed by histological 
examination of liver tissue obtained by needle biopsy 
or other procedures; or (2) 1 or more hepatic space-
occupying lesions were detected by ultrasonography or 
computed tomography and were shown to have vascu-
lar patterns typical of HCC by angiography,  triple-
phase spiral computed tomography or contrast-enhanced 
magnetic resonance imaging.  CVD complications include 
acute coronary syndrome,  cerebral infarction and 
cerebral hemorrhage which were diagnosed by CT or 
coronary angiography.
　 Statistical methods. Descriptive statistics were 
computed for all the variables,  including medians and 
ranges for the continuous variables and frequencies 
for the categorical factors.  The presence of speciﬁc 
categorical features across diﬀerent subsets was 
compared using Fisherʼs exact test or G-test.  The 
across-group comparisons of the numerical data were 
performed using the Studentʼs t-test for normally dis-
tributed data and the Mann-Whitney U-test for non-
normally distributed data.
　 The start date for the purposes of the analyses was 
the date of the biopsy.  The patients were followed 
until they either underwent liver transplantation or 
died.  The termination date for analysis was the date 
of liver transplantation or death.  The patients were 
censored at the time of transplantation or at the last 
follow-up visit.  A time-to-failure analysis (Kaplan-
Meier) was performed,  and the log-rank test was used 
for across-group comparisons.
Results
　 Characteristics of the Patients with 
advanced NASH, advanced CHC and mild 
NASH. The median age in the advanced NASH 
patients was 69 (range,  55-81) years (Table 1).  The 
median BMI was 27.4 (range,  22.9-35.2).  Twelve 
patients (60ｵ) had diabetes mellitus,  8 (40ｵ) had 
hyperlipidemia and 7 (35ｵ) had hypertension.
　 The median age in the advanced CHC patients was 
69.5 (range,  57-85) years (Table 1).  The median BMI 
was 27.0 (range,  24.2-35.8).  Seven patients (35ｵ) 
had diabetes mellitus,  2 (10ｵ) had hyperlipidemia and 
10 (50ｵ) had hypertension.  The patients with advanced 
NASH had higher platelet counts (p＝0.010),  higher 
serum gamma-glutamyl transpeptidase levels (p＝
0.050),  higher albumin levels (p＝0.028),  higher total 
cholesterol levels (p＝0.022) and lower fasting blood 
sugar levels (p＝0.035) than those with advanced 
CHC (Table 1).
　 Of the 19 mild NASH patients,  the median age was 
67 (range,  52-78) years (Table 2).  The median BMI 
was 24.8 (range,  20.5-31.2).  Twelve patients (63.2ｵ) 
had diabetes mellitus,  8 (42.1ｵ) had hyperlipidemia 
and 14 (73.7ｵ) had hypertension.  Hypertension was 
more common in the mild NASH patients than in the 
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advanced NASH patients (p＝0.025) (Table 2).  The 
advanced NASH patients had lower platelet counts (p
＜0.001),  lower prothrombin times (p＜0.001),  higher 
total bilirubin levels (p＝0.048),  lower total choles-
terol levels (p＝0.034) and lower alanine aminotrans-
ferase levels (p＝0.038) than those with mild NASH 
(Table 2).
　 Comparisons of overall survival in the 
advanced NASH group with advanced CHC and 
mild NASH groups. During a mean follow-up 
period of 85.6 months (median,  92.5 months; range,  
36-98 months),  5 patients (25.0ｵ) died in the advanced 
NASH group.  The causes of death were HCC (2 
patients),  liver failure (2 patients) and cerebral infarc-
tion (1 patient) in the advanced NASH group.  During 
a mean follow-up period of 81.3 months (median,  87.5 
months; range,  41-97 months),  10 patients (50.0ｵ) 
died in the advanced CHC group.  The causes of death 
were HCC (7 patients) and liver failure (3 patients) in 
the advanced CHC group.  During a mean follow-up 
period of 90.8 months (median,  92 months; range,  
61-98 months),  only 1 patient died of acute myocar-
dial infarction in the mild NASH group.  The overall 
survival in the advanced NASH group was not signiﬁ-
cantly diﬀerent compared to those in the advanced 
CHC (Fig.  1A) or mild NASH (Fig.  1B) groups.  
There was a statistical trend towards association 
between the severity of NASH stage and overall sur-
vival,  but the trend did not reach statistical signiﬁ-
cance (p＝0.098).
　 Comparisons of liver-related complications- 
and HCC-free survival in the advanced NASH 
with advanced CHC and mild NASH groups.
During the follow-up period,  8 patients (40ｵ) devel-
oped HCC and 4 (20ｵ) developed liver failure in the 
advanced NASH group.  In the advanced CHC group,  
8 patients (40ｵ) developed HCC and 4 (20ｵ) devel-
oped liver failure.  Neither HCC nor liver failure was 
observed in the mild NASH group.  Liver-related 
complications- and HCC-free survival were not sig-
niﬁcantly diﬀerent between the advanced NASH and 
advanced CHC groups (Figs.  2A and 3A).  However,  
liver-related complications- and HCC-free survival 
were signiﬁcantly reduced in the advanced NASH 
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Month 0 24 48 72 96
Advanced NASH 20 20 18 16 15
Mild NASH 19 19 19 18 18
(B) Advanced NASH versus mild NASH
P = 0.098
Advanced NASH
Mild NASH
1
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0.7
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0.5
0.4
0.3
0.2
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0
0 12 24 36 48 60 72 84 96
Overall survival
P = 0.301
(A) Advanced NASH versus advanced CHC
Month 0 24 48 72 96
Advanced NASH 20 20 18 16 15
Advanced CHC 20 20 19 16 10
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0
0 12 24 36 48 60 72 84 96
Fig. 1　 A,  The cumulative probabilities of overall survival for the NASH with advanced ﬁbrosis group (advanced NASH) (solid line) and 
for the matched hepatitis C virus (HCV)-related advanced ﬁbrosis group (advanced CHC) (dotted line).  There was no signiﬁcant diﬀerence 
in overall survival between the 2 groups (p＝0.301); B,  The cumulative probabilities of overall survival for the advanced NASH group 
(solid line) and the matched NASH with mild ﬁbrosis group (mild NASH) (dotted line).  There was a statistical trend towards association 
between the severity of NASH stage and overall survival,  but the trend did not reach statistical signiﬁcance (p＝0.098).
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Month 0 24 48 72 96
Advanced NASH 20 19 16 15 8
Mild NASH 19 19 19 19 19
(B) Advanced NASH versus mild NASH
P < 0.001
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Mild NASH
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Liver-related complication-free survival
Month 0 24 48 72 96
Advanced NASH 20 19 16 15 8
Advanced CHC 20 18 15 10 8
P = 0.460
(A) Advanced NASH versus advanced CHC
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0 12 24 36 48 60 72 84 96
Fig. 2　 A,  The cumulative probabilities of liver-related complication-free survival for the advanced NASH group (solid line) and the 
matched advanced CHC group (dotted line).  There was no signiﬁcant diﬀerence in liver-related complication-free survival between the 2 
groups (p＝0.460); B,  The cumulative probabilities of liver-related complication-free survival in the advanced NASH group (solid line) and 
the mild NASH group (dotted line).  Liver-related complication-free survival was signiﬁcantly reduced in the advanced NASH group com-
pared to the mild NASH group (p＜0.001).
HCC-free survival
Month 0 24 48 72 96
Advanced NASH 20 19 18 15 12
Advanced CHC 20 18 16 14 12
P = 0.518
(A) Advanced NASH versus advanced CHC
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Month 0 24 48 72 96
Advanced NASH 20 19 18 15 12
Mild NASH 19 19 19 19 19
(B) Advanced NASH versus mild NASH
P = 0.004
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Fig. 3　 A,  The cumulative probabilities of HCC-free survival for the advanced NASH group (solid line) and the matched advanced CHC 
group (dotted line).  There was no signiﬁcant diﬀerence in HCC-free survival between the 2 groups (p＝0.518); B,  The cumulative proba-
bilities of HCC-free survival in the advanced NASH group (solid line) and the mild NASH group (dotted line).  HCC-free survival was sig-
niﬁcantly reduced in the advanced NASH group compared to the mild NASH group (p＝0.004).
group compared to the mild NASH group (Figs.  2B 
and 3B).
　 Comparisons of CVD complication-free sur-
vival in the advanced NASH group with 
advanced CHC and mild NASH groups.
During the follow-up period,  2 patients (10ｵ) devel-
oped cerebral infarctions in the advanced NASH 
group.  One cerebral infarction was observed in the 
advanced CHC group.  Two cerebral infarctions (10.5ｵ) 
and 4 acute coronary syndromes (21.1ｵ) were observed 
in the mild NASH group.  The CVD complication-free 
survival in the advanced NASH group was not signiﬁ-
cantly diﬀerent compared to those in the advanced 
CHC (Fig.  4A) or mild NASH (Fig.  4B) groups.
Discussion
　 The major ﬁnding of our study is that the outcomes 
of NASH with advanced ﬁbrosis may be worse than 
those of NASH with mild ﬁbrosis regarding liver-
related complications,  including HCC development in 
female patients.  Thus,  although more attention has 
been paid to male patients because male gender has 
been reported to be an HCC risk factor in NASH 
patients [22,  30,  31],  female NASH patients should 
also be recognized as a high-risk population that,  if 
their histological stage is high,  are more likely to 
suﬀer liver-related complications.  Another distinctive 
aspect of our study is that we focused on female 
patients,  and age and BMI were adjusted between 
each study group,  while previous studies comparing 
NASH and CHC cirrhosis adjusted for age and sex 
only [29,  34,  35].  As mentioned above,  age,  gender,  
obesity and ﬁbrosis are closely related to the progno-
sis of NASH in the Japanese population.  In addition,  
obesity and diabetes mellitus are recognized as risk 
factors for HCC and cardiovascular disease [31,  
36-38].  Thus,  our study has an advantage in that age,  
gender and BMI were adjusted between each study 
group.
　 Our ﬁnding that the reduced liver-related complica-
tion-free survival in the group of advanced NASH 
patients compared to the mild NASH group is consis-
tent with several studies [39,  40],  although these 
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CVD complication-free survival
Month 0 24 48 72 96
Advanced NASH 20 19 19 18 18
Mild CHC 20 20 19 19 19
P = 0.575
(A) Advanced NASH versus advanced CHC
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(B) Advanced NASH versus mild NASH
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Fig. 4　 A,  The cumulative probabilities of cardiovascular/cerebrovascular disease (CVD) complications for the advanced ﬁbrosis NASH 
group (solid line) and the group of matched advanced ﬁbrosis CHC group (dotted line).  There was no signiﬁcant diﬀerence in the CVD 
complication-free survival between the 2 groups (p＝0.575); B,  The cumulative probabilities of CVD complication-free survival for the 
advanced ﬁbrosis NASH group (solid line) and the matched mild NASH group (dotted line).  There was no signiﬁcant diﬀerence in CVD 
complication-free survival between the 2 groups (p＝0.200).
study cohorts were not age-,  sex- and BMI-matched.  
Our study is also consistent with prior studies [22,  
41] showing that advanced ﬁbrosis is one of the risk 
factors for developing HCC in NASH patients.  
Notably,  our study showed that advanced ﬁbrosis may 
be independent of age,  BMI and diabetes mellitus as 
risk factors for developing HCC in NASH patients.
　 The similar overall survival rates we observed for 
NASH-associated and HCV-associated cirrhosis are 
consistent with the results of several previous reports 
[29,  34],  but are in contrast to those of Sanyal et al. 
[35] that found NASH-associated cirrhosis to have a 
lower mortality rate than HCV-associated cirrhosis.  
A possible reason for this inconsistency is that the 
large sample size and long-term (more than 20 years) 
follow-up in Sanyalʼs study provided suﬃcient power 
to reach statistical signiﬁcance.  Another possible 
reason is racial diﬀerence,  given that our results are 
similar to those of Yatsuji et al. [29] in a Japanese 
population,  which showed no signiﬁcant diﬀerences in 
the overall survival rates between the NASH and 
HCV groups.  Furthermore,  our ﬁnding of no signiﬁ-
cant diﬀerence in the liver-related complication-free 
survival between the NASH and HCV groups is con-
sistent with the results of Yatsuji et al. [29] but in 
contrast to those of Sanyal et al. [35].  The possible 
reasons for the inconsistency are the same as those 
mentioned above.
　 Yatsuji et al. [29] showed that the 5-year overall 
survival rate of NASH-associated cirrhosis was 75.2ｵ,  
while it was almost 90ｵ in our study,  although both 
study populations were Japanese.  A possible reason 
for this inconsistency is the diﬀerence in the fre-
quency of diabetes mellitus and gender composition 
between the studies.  Our study population was com-
prised of female patients,  and the frequency of diabe-
tes mellitus in this population was relatively low 
compared to the study population in Yatsuji et al. 
[29],  which might have inﬂuenced our ﬁndings of a 
lower frequency of CVD-related or liver-related com-
plications.  Another possible reason is that the liver 
function based on serum albumin level and total biliru-
bin level in our study population was relatively good 
compared to the study population in Yatsuji et al. [29],  
which might have led to better overall survival in our 
study.
　 Because of the small sample size of our study 
cohorts,  we could not use a Cox proportional-hazards 
regression model in our study population.  In addition,  
some of the baseline characteristics were signiﬁcantly 
diﬀerent between the advanced NASH,  advanced CHC 
and mild NASH groups.
　 In conclusion,  female patients with NASH and 
advanced ﬁbrosis may have a less favorable prognosis 
than age- and BMI-matched cohorts with NASH and 
mild ﬁbrosis regarding liver-related complications,  
including HCC development.  In contrast,  the progno-
sis of female patients with NASH and advanced 
ﬁbrosis may be similar to that of age-,  BMI- and 
ﬁbrosis grade-matched cohorts with CHC,  although 
the results were preliminary.  Larger cohort studies 
with much longer follow-ups are needed to conﬁrm our 
data.
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